Medicines play an important part in promoting well-being, preventing ill-health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.
Medicines Management can be defined in several ways:
- The clinical, cost-effective, safe and secure handling of medicines
- A system of processes and behaviours that determines how medicines are used by the NHS and patients
- Enabling people to make the best possible use of medicines
Our goal is to achieve the best health outcomes for patients where medicines are involved.
If you have any medicines queries please contact NHS Blackpool CCG’s Medicines Management team on 01253 951306 or email firstname.lastname@example.org
Please see the links below for background information on the Red, Amber, Green (RAG) classification in relation to prescribing responsibility and also our RAG list of drugs.
Prescribing position statements:
- 28 day prescribing
- Emollients and Sunscreens
- Generic Biosimilar Medicines Position Statement
- Generic Prescribing Guidelines – Updated December 2017
- Gluten-Free Foodstuffs
- Health Professionals e cigarettes briefing Blackpool Council – Blackpool CCG supports the position of Blackpool Council on e-cigarettes and advises GPs not to prescribe until further guidance is available. Patients who require support for smoking cessation may be referred to the Stop Smoking Service.
- Ivabradine Prescribing Information Sheet
- Nutritional Supplements post Bariatric surgery
- Ophthalmology Macular Pathways
- PKU (Phlexy-Vit)
- Pregabalin Prescribing
- Prescribing For Clinical Need – Low Priority Medicines (General)
- Prescribing for Clinical Need – ONS in care and nursing homes
- Prescribing for Clinical Need – Thickeners
- Prescribing for Clinical Need – Holiday Medication
- Prophylactic Supply of catheters post pelvic organ prolapse
- Policy for the provision of Glucose Monitoring Devices
- Policy for insulin pump provision
- Sip Feeds
- Soluable Analgesics
- Stoma Deodorants and Air fresheners Position Statement
- Trans Anal Irrigation Position Statement
- Vitamins and Minerals
- Vitamin D Position Statement
- Zero Risk Schemes in advance of NICE Guidance
- Antihyperglycaemic therapy in adults with type 2 diabetes
- Antimicrobial Guidelines (Fylde coast)
- Asthma Summary Guidelines
- Axial Spondyloarthritis Pathway
- Blood glucose meters and test strips for patients with Type 2 Diabetes
- Chronic Non-Cancer Pain Guideline
- Constipation Pathway Guidance
- Degarelix Prescribing Information Sheet
- Dementia Medicines Prescribing Sheet
- Erectile dysfunction Guideline
- Gastroenterology Biologics Pathway
- Good practice guidelines for Gender Dysphoria
- Good Prescribing in Primary Care
- Gender Dyshoria protocol and service guidance (interim)
- Home Monitoring of Blood Glucose Levels Guideline
- Management of Psoriasis in Primary Care Guideline
- Management of Behavioural & Psychological Symptoms of Dementia (BPSD)
- Neuropathic Pain Guidelines
- LMMG Headache Guideline
- Palliative Care Clinical Practice Summary
- Pathway for prevention of stroke and systemic embolism in non-valvular AF
- Pharmacological Management of Adults with Non-Cancer Pain
- Prescription Management of Stoma and Incontinence Products
- Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy
- Primary Care Good Prescribing Guide
- Psoriatic Arthritis Pathway
- Psoriasis Biologics Pathway
- ONS in Primary Care
- Rheumatoid Arthritis High Cost Drugs Pathway
- SIP Feeds Blackpool Guidance Nov 13
- Specialist Infant Formula Feeds prescribing guidelines
- Ulipristal (Esmya® ) for Treatment of Uterine Fibroids Prescribing Guideline
SHARED CARE: Guidelines and information documents
Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.
For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.
- Drugs included in GP+ scheme:
- Drugs not included in GP+ scheme:
Patient Group Directions
A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.
Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.
Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.
Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document: www.lancsmmg.nhs.uk/pgds
Patient information leaflets
Primary Care Rebate Schemes
Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.
Current Primary Care Rebate Schemes in place (October 2018):
- Fencino (Fentanyl) – Started 1 October 2018
- Firmagon (Degarelix) – Started 1 September 2016
- GlucoRx – Started 1 July 2018
- Januvia (Sitagliptin) – Started 1 September 2018
- Lixiana (Edoxaban) – Started 1 October 2018
- Seretide (Fluticasone / Salmeterol) – Started 1 January 2018
- Spiolto (Tiotropium + Olodaterol) – Started 1 October 2018
Help reduce waste medication
We have launched a campaign to reduce waste medication. Find out more about it here.